Testing ALERT With GTO in Middle Schools
Launched by RAND · Jan 20, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Testing ALERT With GTO in Middle Schools," is looking to see how well a program called Project ALERT works to help prevent substance abuse among middle school students. The study will also use a tool called Getting To Outcomes to support the program's effectiveness. The goal is to gather information on how this program can be improved and how well it helps students stay away from drugs and alcohol.
If you're a 7th grader, typically aged 12-14, attending one of the participating schools, you might be eligible to join this study. Teachers and school staff who want to be part of the research are also welcome to participate. Those who join can expect to engage in activities that promote awareness and prevention of substance abuse, and there will be opportunities for both students and teachers to share their experiences. It's important to know that this study is currently looking for participants, so if you or someone you know fits the criteria, it could be a great opportunity to contribute to a meaningful cause!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Eligibility for student participants: all students in 7th grade, primarily aged 12-14, attending school at one of the enrolled schools in the study.
- • Eligibility for school staff participants: all educators interested in enrolling in the study at each of the enrolled schools.
- Exclusion Criteria:
- • Not meeting eligibility criteria
- • Note: the age range is from 11 to 70 to account for both the student AND teacher populations.
About Rand
RAND is a leading nonprofit research organization dedicated to improving policy and decision-making through rigorous analysis and evidence-based solutions. With a commitment to advancing public health, RAND conducts innovative clinical trials that aim to evaluate new treatments, interventions, and health policies. By leveraging multidisciplinary expertise and a collaborative approach, RAND strives to translate research findings into actionable insights that enhance healthcare outcomes and inform stakeholders across the medical and policy landscapes. Through its comprehensive studies, RAND plays a pivotal role in shaping the future of health and wellness on a global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
Matthew Chinman, PhD
Principal Investigator
RAND
Eric Pedersen, PhD
Principal Investigator
University of Southern California
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials